drugset / Trial / NCT07622706
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Timeline
- Start
- 2026-05-30
- Primary completion
- 2028-05-30
- Completion
- 2029-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firmonertinib | Small molecule | 80 mg | Oral |
| Subject | Firmonertinib | Small molecule | 160 mg | Oral |